Guardant Health (NASDAQ:GH) Reaches New 1-Year High – Still a Buy?

Posted by George Bondi on Sep 18th, 2026

Guardant Health, Inc. (NASDAQ:GH – Get Free Report)’s share price reached a new 52-week high during mid-day trading on Wednesday . The stock traded as high as $179.30 and last traded at $175.65, with a volume of 2851744 shares. The stock had previously closed at $167.84.

More Guardant Health News

Here are the key news stories impacting Guardant Health this week:

Positive Sentiment: Guardant Health was described as nearing a technical buy point as its sales outlook brightened, supporting investor confidence in continued revenue growth. Guardant Health Nears Buy Point As Sales Outlook Brightens
Positive Sentiment: A comparison of second-quarter testing and diagnostics companies highlighted Guardant Health’s strong performance. The company’s revenue rose 44.3% year over year to approximately $335 million and exceeded analyst expectations, while its quarterly loss was narrower than forecast. Testing & diagnostics services stocks Q2 results: Benchmarking Guardant Health
Positive Sentiment: The stock reached a new one-year high, reflecting strong momentum and investor demand following its recent rally. The move could attract additional momentum-oriented buyers, though it also raises the risk of profit-taking. Guardant Health Reaches New 1-Year High – What’s Next?
Neutral Sentiment: Director Musa Tariq sold 116 shares for about $20,300, reducing his position by 1%. The transaction was executed under a pre-arranged Rule 10b5-1 plan, making it a limited and less concerning signal. SEC Form 4 filing
Negative Sentiment: Several insiders reported sales: Director Alex M. Azar II sold 826 shares for approximately $144,550, Director Steve Krognes sold 6,674 shares for roughly $1.17 million, and CTO Darya Chudova sold 7,738 shares for about $1.38 million. The transactions reduced their holdings substantially and could raise profit-taking concerns, although the sales were disclosed through SEC filings and some were conducted under pre-arranged plans. Insider sale SEC filing

Analyst Upgrades and Downgrades

Several research firms recently commented on GH. Bank of America boosted their price target on Guardant Health from $135.00 to $190.00 and gave the stock a “buy” rating in a research note on Monday, July 6th. TD Cowen reaffirmed a “buy” rating on shares of Guardant Health in a research report on Tuesday, August 25th. JPMorgan Chase & Co. raised their price target on shares of Guardant Health from $185.00 to $195.00 and gave the stock an “overweight” rating in a research report on Friday, July 31st. BTIG Research reissued a “buy” rating and set a $195.00 price objective on shares of Guardant Health in a report on Wednesday, September 2nd. Finally, The Goldman Sachs Group restated a “buy” rating and issued a $210.00 target price on shares of Guardant Health in a research note on Friday, July 31st. One analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $188.12.

Check Out Our Latest Analysis on Guardant Health

Guardant Health Stock Up 4.7%

The stock has a market capitalization of $24.57 billion, a P/E ratio of -52.46 and a beta of 1.57. The company has a 50 day moving average of $160.71 and a 200-day moving average of $127.10.

Guardant Health (NASDAQ:GH – Get Free Report) last released its earnings results on Thursday, July 30th. The company reported ($0.42) earnings per share for the quarter, beating the consensus estimate of ($0.76) by $0.34. The business had revenue of $334.98 million for the quarter, compared to the consensus estimate of $314.23 million. The firm’s revenue for the quarter was up 44.3% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.44) EPS. Equities analysts forecast that Guardant Health, Inc. will post -2.98 EPS for the current fiscal year.

Insider Buying and Selling at Guardant Health

In related news, Director Alex M. Azar II sold 826 shares of the stock in a transaction dated Wednesday, September 16th. The shares were sold at an average price of $175.00, for a total transaction of $144,550.00. Following the sale, the director owned 825 shares in the company, valued at $144,375. This represents a 50.03% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Terilyn Monroe sold 46,300 shares of the firm’s stock in a transaction dated Wednesday, August 12th. The stock was sold at an average price of $165.12, for a total transaction of $7,645,056.00. Following the completion of the transaction, the insider directly owned 22,979 shares in the company, valued at $3,794,292.48. This represents a 66.83% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 442,262 shares of company stock worth $69,813,286. 5.60% of the stock is owned by company insiders.

Institutional Trading of Guardant Health

Institutional investors and hedge funds have recently made changes to their positions in the stock. ABS Investment Management LLC acquired a new position in Guardant Health during the 2nd quarter valued at approximately $345,069,000. Franklin Resources Inc. lifted its position in Guardant Health by 14.9% in the 4th quarter. Franklin Resources Inc. now owns 3,361,547 shares of the company’s stock valued at $343,348,000 after purchasing an additional 435,232 shares during the last quarter. Geode Capital Management LLC lifted its position in Guardant Health by 9.4% in the 4th quarter. Geode Capital Management LLC now owns 3,213,657 shares of the company’s stock valued at $328,297,000 after purchasing an additional 277,001 shares during the last quarter. The Manufacturers Life Insurance Company acquired a new stake in shares of Guardant Health in the 2nd quarter worth approximately $208,592,000. Finally, William Blair Investment Management LLC bought a new position in shares of Guardant Health in the second quarter valued at approximately $196,737,000. 92.60% of the stock is currently owned by institutional investors and hedge funds.

About Guardant Health

(Get Free Report)

Guardant Health, Inc (NASDAQ:GH) is a precision oncology company that develops blood-based diagnostic tests designed to help detect cancer, guide treatment decisions and monitor patients over time. Its liquid biopsy technologies analyze tumor-related signals in blood, reducing the need for tissue biopsies in certain clinical and research settings.

The company’s products include Guardant360 tests, which profile advanced cancers and can help identify potentially actionable genomic alterations; Guardant Reveal, which is used to assess residual disease and recurrence risk; and Guardant Shield, a blood-based screening test for colorectal cancer.